The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

enprostil     methyl7-[(1R,2S,3R)-3- hydroxy-2-[(E,3S)-3...

Synonyms: Gardrine, Camleed, Syngard, Camleed (TN), CHEMBL2104194, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of enprostil


High impact information on enprostil


Chemical compound and disease context of enprostil


Biological context of enprostil


Anatomical context of enprostil

  • The antroduodenal coordination, frequency and amplitude of antral contractions, and size of antral area were reduced, whereas the time during which the pylorus was wide open (greater than 5 mm) was increased after enprostil [6].
  • Thirty-five and 70 micrograms of enprostil administered intragastrically reduced total eight-hour gastric acid secretion by 58 percent and 82 percent, respectively (p less than 0.05) [19].
  • Reduction by enprostil of aspirin-induced blood loss from human gastric mucosa [20].
  • Digestive system complaints were reported more frequently in the enprostil group, whereas central nervous system complaints were more than twice as frequent in the cimetidine group [21].
  • After enprostil administration, the pH of both aspirated gastric juice and washings was significantly elevated, suggesting that an antisecretory dose had been used [20].

Associations of enprostil with other chemical compounds

  • The pH values during the night were similar in the groups treated with enprostil 35 micrograms b.i.d. and 70 micrograms h.s. During the daytime, the readings at or above pH 4 were placebo, 5%; cimetidine, 21%; enprostil 35 micrograms b.i.d., 34% [1].
  • We studied whether enprostil, a synthetic prostaglandin E2 derivative, might inhibit gastrin release and the trophic effects on gastric oxyntic mucosa induced by prolonged treatment with an inhibitor of hydrogen-potassium-stimulated adenosine triphosphatase, the substituted benzimidazole BY 831-78 [8].
  • Ranitidine suppressed gastric acid secretion by 95 percent, which was similar to the suppression achieved with the 70 microgram dose of enprostil [19].
  • These observations may be related to the inhibitory effect of enprostil on the activation of adenylate cyclase in gastric parietal cells, which follows binding of histamine to H2 receptors [14].
  • Preservation of the integrity of the microvasculature of the gastric mucosa against the effects of cyclo-oxygenase inhibitors, ethanol, and other damaging agents may contribute to the mucosal protective effects of enprostil and some other prostaglandins [14].

Gene context of enprostil


Analytical, diagnostic and therapeutic context of enprostil

  • Ten healthy subjects were studied on two separate days, once after oral administration of one capsule of enprostil 35 micrograms 1 hour before the ingestion of 500 mL of meat soup and once without drug administration before the meal [6].
  • Antroduodenal motility studied by real-time ultrasonography. Effect of enprostil [6].
  • After an overnight fast, a gastroscope was inserted and the antral mucosa was sprayed with a 10-mL test solution containing either enprostil (70 micrograms) or its vehicle (control) [7].
  • Scanning electron microscopy of rat fundic mucosa after enprostil administration (50 to 100 micrograms/kg) revealed the presence of thin veil-like layers covering the epithelial surface, which was interpreted as an increase in mucus secretion [25].
  • In healthy human volunteers, a single oral dose of enprostil (35 micrograms) inhibited basal gastric acid output by a mean of 71 percent, pentagastrin-stimulated output by 46 percent, sham-meal-stimulated output by 48 percent, and histamine-stimulated output by 16 percent [4].


  1. Antisecretory and serum gastrin lowering effect of enprostil in patients with duodenal ulcer disease. Mahachai, V., Walker, K., Sevelius, H., Thomson, A.B. Gastroenterology (1985) [Pubmed]
  2. Treatment of gastric ulcer with enprostil. Navert, H. Am. J. Med. (1986) [Pubmed]
  3. Protective effect of enprostil against aspirin-induced gastroduodenal mucosal injury in man. Comparison with cimetidine and sucralfate. Stiel, D., Ellard, K.T., Hills, L.J., Brooks, P.M. Am. J. Med. (1986) [Pubmed]
  4. Effect of a single oral dose of enprostil on gastric secretion and gastrin release. Studies in healthy volunteers and patients with pernicious anemia. Buchanan, N., Laferla, G., Hearns, J., Buchanan, K.D., Crean, G.P., McColl, K.E. Am. J. Med. (1986) [Pubmed]
  5. Copresence of prostaglandin EP2 and EP3 receptors on gastric enterochromaffin-like cell carcinoid in African rodents. Naribayashi-Inomoto, Y., Ding, M., Nakata, H., Narumiya, S., Sugimoto, Y., Honda, A., Ichikawa, A., Chiba, T., Kinoshita, Y. Gastroenterology (1995) [Pubmed]
  6. Antroduodenal motility studied by real-time ultrasonography. Effect of enprostil. Hausken, T., Odegaard, S., Berstad, A. Gastroenterology (1991) [Pubmed]
  7. Human antral damage induced by alcohol is potentiated by enprostil. Cohen, M.M., Yeung, R., Wang, H.R., Clark, L. Gastroenterology (1990) [Pubmed]
  8. Enprostil reduces the increase of gastric corpus mucosal mass induced by the hydrogen-potassium-stimulated adenosine triphosphatase inhibitor BY 831-78 in the rat. Inauen, W., Rohner, C., Koelz, H.R., Herdmann, J., Schürer-Maly, C.C., Varga, L., Halter, F. Gastroenterology (1989) [Pubmed]
  9. Treatment of duodenal ulcer with enprostil, a prostaglandin E2 analogue. Bright-Asare, P. Am. J. Med. (1986) [Pubmed]
  10. Platelet function in patients receiving enprostil. Bunce, I., Ward, M., Solomon, E., Cowen, A. Am. J. Med. (1986) [Pubmed]
  11. Weakness of mucosal barrier in portal hypertensive gastropathy of alcoholic cirrhosis. Effects of propranolol and enprostil. Payen, J.L., Cales, P., Pienkowski, P., Sozzani, P., Kervran, A., Frexinos, J., Pascal, J.P. J. Hepatol. (1995) [Pubmed]
  12. The effect of the E2 prostaglandin enprostil, and the somatostatin analogue SMS 201 995, on the growth of a human gastric cell line, MKN45G. Watson, S.A., Durrant, L.G., Morris, D.L. Int. J. Cancer (1990) [Pubmed]
  13. Enprostil, a prostaglandin E2 analogue, in the treatment of duodenal ulcer; a multicentre comparison with cimetidine. Jazrawi, R.P., Northfield, T.C., Reed, P.I., Cockel, R., Schillers, K.F., Barkers, E.S. Aliment. Pharmacol. Ther. (1988) [Pubmed]
  14. Effects of enprostil on platelets, endothelial cells, and other cell types, and second messenger systems by which these effects are mediated. Allison, A.C., Kowalski, W.J., Strulovici, B. Am. J. Med. (1986) [Pubmed]
  15. Prostanoid inhibition of canine parietal cells. Soll, A.H., Chen, M.C., Amirian, D.A., Toomey, M., Alvarez, R. Am. J. Med. (1986) [Pubmed]
  16. Effect of enprostil on basal and meal-stimulated gastric acid and pepsin secretion, serum gastrin and gastric emptying in healthy persons. Berstad, K., Massey, H., Berstad, A. Aliment. Pharmacol. Ther. (1988) [Pubmed]
  17. No abortion-inducing effect of the ulcer-healing dose of the synthetic prostaglandin E2 analogue enprostil in first trimester. Jacobson, J., Bergquist, C., Rydnert, J., Bokström, H., Huovinen, K. Acta obstetricia et gynecologica Scandinavica. (1990) [Pubmed]
  18. Effects of enprostil on gastric endocrine secretion during chronic administration of lansoprazole. Omura, N., Kashiwagi, H., Aoki, T., Omura, K., Fukuchi, Y. J. Gastroenterol. (1997) [Pubmed]
  19. Enprostil, a synthetic prostaglandin E2 analogue, inhibits meal-stimulated gastric acid secretion and gastrin release in patients with duodenal ulcer. Thomas, F.J., Koss, M.A., Hogan, D.L., Isenberg, J.I. Am. J. Med. (1986) [Pubmed]
  20. Reduction by enprostil of aspirin-induced blood loss from human gastric mucosa. Hawkey, C.J., Simpson, G., Somerville, K.W. Am. J. Med. (1986) [Pubmed]
  21. Comparison of enprostil and cimetidine in active duodenal ulcer disease. Summary of pooled European studies. Winters, L. Am. J. Med. (1986) [Pubmed]
  22. Enprostil, a prostaglandin-E(2) analogue, inhibits interleukin-8 production of human colonic epithelial cell lines. Toshina, K., Hirata, I., Maemura, K., Sasaki, S., Murano, M., Nitta, M., Yamauchi, H., Nishikawa, T., Hamamoto, N., Katsu, K. Scand. J. Immunol. (2000) [Pubmed]
  23. Enprostil. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the treatment of peptic ulcer disease. Goa, K.L., Monk, J.P. Drugs (1987) [Pubmed]
  24. Suppression of alimentary lipemia in man by a prostaglandin analogue (enprostil). Schwartz, K.E., Saito, T. Atherosclerosis (1989) [Pubmed]
  25. Stimulatory effect of enprostil, an anti-ulcer prostaglandin, on gastric mucus secretion. Waterbury, L.D., Mahoney, J.M., Peak, T.M., Cohn, R.G., Garay, G.L. Am. J. Med. (1986) [Pubmed]
WikiGenes - Universities